Clinical Trial Update: Break Wave(TM) Extracorporeal Lithotripter First-in-Human Study [NA]

View source ↗

Summary

SonoMotion's Break Wave Extracorporeal Lithotripter is in a first-in-human study to treat nephrolithiasis and urolithiasis and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nephrolithiasis
• Urolithiasis

Snippet

Sponsor: SonoMotion | Conditions: Renal Calculi, Urinary Calculi | NA | Status: RECRUITING